Alerts and Notices
SynopsisLi-Fraumeni syndrome (LFS) was first defined by Frederick Li and Joseph Fraumeni Jr. in 1969 based on the history of rhabdomyosarcoma in 4 different families. A patient with LFS:
- Has been diagnosed with a sarcoma before the age of 45 years.
- Has a first-degree relative with any type of cancer who was also diagnosed before age 45.
- Has a third family member (first- or second-degree relative) with a cancer diagnosis in a similar timeline, or a sarcoma at any age. The third member must also be in the same familial lineage as the primary and secondary family members.
LFS affects both pediatric and adult populations. Osteosarcoma is the most common malignancy in children (30%), and breast cancer is the most common in adults (79% of women with LFS). LFS shows heterogeneity in terms of age of onset and type of malignancy.
Geographically, LFS is highly prevalent in Brazil due to a founder effect mutation. Many individuals of Brazilian descent with LFS have a specific TP53 mutation (p.R337H) that predisposes these individuals to adult papillary thyroid cancer, renal cancer, and lung adenocarcinoma, more so than other carriers of the TP53 gene. This may suggest a variant form of LFS.
Z15.01 – Genetic susceptibility to malignant neoplasm of breast
Z15.09 – Genetic susceptibility to other malignant neoplasm
428850001 – Li-Fraumeni syndrome
Differential Diagnosis & Pitfalls
- Hereditary nonpolyposis colorectal cancer (Lynch syndrome) – Associated with colorectal, small bowel, hematologic, and brain malignancies.
- CHEK2 cancer susceptibility – Associated with breast, colorectal, and prostate malignancies.
- BRCA1 / BRCA2-associated hereditary breast and ovarian cancer – Associated with breast, ovary, pancreas, prostate, and skin (melanoma) malignancies.